retatrutide dosing clinical trial Guide for Researchers retatrutide dosing schedule clinical trial

Who It's For (Based on Trial Inclusion Criteria) BMI 30 (obesity) OR BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, sleep apnea) Adults ages 1875 (some trials include narrower age ranges) People who have tried lifestyle interventions (diet and exercise) without sufficient weight loss Those with type 2 diabetes seeking both glucose control and weight loss People with obesity-related conditions that would improve with major weight reduction Who Should Avoid Retatrutide Based on trial exclusion criteria and the drug's mechanism, retatrutide is likely not appropriate for: Pregnancy or breastfeeding: Not studied in these populations

Much of the spotlight has been on their impressive ability to help people shed significant amounts of weight, but the story doesnt end there

Tirzepatide can be used safely in patients with Hashimoto's who meet obesity treatment criteria, provided thyroid function is optimized and contraindications are excluded (personal or family history of medullary thyroid carcinoma or MEN2)

Front Med 2021;8:653634

As with any medication, Retatrutide has potential side effects

Ethics declarations Conflict of interest The authors declare no conflict of interest that could have influenced the submitted work